Search Results - "Hagihara, Hiroaki"

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab by Takeuchi, Yasuto, Nouso, Kazuhiro, Fujioka, Shin-Ichi, Kariyama, Kazuya, Kobashi, Haruhiko, Uematsu, Shuji, Moriya, Akio, Hagihara, Hiroaki, Takabatake, Hiroyuki, Nakamura, Shinichiro, Yabushita, Kazuhisa, Kikuchi, Tatsuya, Oyama, Atsushi, Adachi, Takuya, Wada, Nozomu, Onishi, Hideki, Shiraha, Hidenori, Takaki, Akinobu

“…The IMbrave 150 trial revealed the usefulness of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (HCC), making it…”
Get full text

Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma by Tanaka, Shigetomi, Shiraha, Hidenori, Nakanishi, Yutaka, Nishina, Shin-Ichi, Matsubara, Minoru, Horiguchi, Shigeru, Takaoka, Nobuyuki, Iwamuro, Masaya, Kataoka, Junro, Kuwaki, Kenji, Hagihara, Hiroaki, Toshimori, Junichi, Ohnishi, Hideki, Takaki, Akinobu, Nakamura, Shinichiro, Nouso, Kazuhiro, Yagi, Takahito, Yamamoto, Kazuhide

“…Loss or decreased expression of runt‐related transcription factor 3 (RUNX3), a tumor suppressor gene involved in gastric and other cancers, has been frequently…”
Get full text

The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma by Kuwaki, Kenji, Nouso, Kazuhiro, Miyashita, Manabi, Makino, Yasuhiro, Hagihara, Hiroaki, Moriya, Akio, Adachi, Takuya, Wada, Nozomu, Yasunaka, Yuki, Yasunaka, Tetsuya, Takeuchi, Yasuto, Onishi, Hideki, Nakamura, Shinichiro, Ikeda, Fusao, Shiraha, Hidenori, Takaki, Akinobu, Okada, Hiroyuki

“…Steroids are often administered at the time of transcatheter arterial chemoembolization (TACE), a standard treatment of hepatocellular carcinoma (HCC), with…”
Get full text

Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma by Kinugasa, Hideaki, Nouso, Kazuhiro, Takeuchi, Yasuto, Yasunaka, Tetsuya, Onishi, Hideki, Nakamura, Shin-ichiro, Shiraha, Hidenori, Kuwaki, Kenji, Hagihara, Hiroaki, Ikeda, Fusao, Miyake, Yasuhiro, Takaki, Akinobu, Yamamoto, Kazuhide

“…Background Radiofrequency ablation (RFA) is a standard therapy for the treatment of hepatocellular carcinoma (HCC) with 3 or fewer tumors of up to 3 cm…”
Get full text

Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer by Nouso, Kazuhiro, Amano, Maho, Ito, Yoichi M., Miyahara, Koji, Morimoto, Yuki, Kato, Hironari, Tsutsumi, Koichiro, Tomoda, Takeshi, Yamamoto, Naoki, Nakamura, Shinichiro, Kobayashi, Sayo, Kuwaki, Kenji, Hagihara, Hiroaki, Onishi, Hideki, Miyake, Yasuhiro, Ikeda, Fusao, Shiraha, Hidenori, Takaki, Akinobu, Nakahara, Taku, Nishimura, Shin-Ichiro, Yamamoto, Kazuhide

“…Background Most of the glycan changes reported in cancers were based on the examinations of a small number of patients or particular proteins. The aim of this…”
Get full text

Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma by Hagihara, Hiroaki, Nouso, Kazuhiro, Kobayashi, Yoshiyuki, Iwasaki, Yoshiaki, Nakamura, Shinichiro, Kuwaki, Kenji, Toshimori, Junichi, Miyatake, Hirokazu, Ohnishi, Hideki, Shiraha, Hidenori, Yamamoto, Kazuhide

“…Background We wished to determine whether pegylated interferon (PEG-IFN) therapy after curative treatment of hepatocellular carcinoma (HCC) prevents a…”
Get full text

The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis by Takeuchi, Yasuto, Ikeda, Fusao, Moritou, Yuki, Hagihara, Hiroaki, Yasunaka, Tetsuya, Kuwaki, Kenji, Miyake, Yasuhiro, Ohnishi, Hideki, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Iwasaki, Yoshiaki, Nouso, Kazuhiro, Yamamoto, Kazuhide

“…Background The single nucleotide polymorphism (SNP) rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat…”
Get full text

Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy by Wada, Nozomu, Ikeda, Fusao, Mori, Chizuru, Takaguchi, Koichi, Fujioka, Shin-Ichi, Kobashi, Haruhiko, Morimoto, Yoichi, Kariyama, Kazuya, Sakaguchi, Kosaku, Hashimoto, Noriaki, Moriya, Akio, Kawaguchi, Mitsuhiko, Miyatake, Hirokazu, Hagihara, Hiroaki, Kubota, Junichi, Takayama, Hiroki, Takeuchi, Yasuto, Yasunaka, Tetsuya, Takaki, Akinobu, Iwasaki, Yoshiaki, Okada, Hiroyuki

“…Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C virus (HCV) serogroup 1 infection. We studied the…”
Get full text

Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis by Nakanishi, Yutaka, Shiraha, Hidenori, Nishina, Shin-ichi, Tanaka, Shigetomi, Matsubara, Minoru, Horiguchi, Shigeru, Iwamuro, Masaya, Takaoka, Nobuyuki, Uemura, Masayuki, Kuwaki, Kenji, Hagihara, Hiroaki, Toshimori, Junichi, Ohnishi, Hideki, Takaki, Akinobu, Nakamura, Shinichiro, Kobayashi, Yoshiyuki, Nouso, Kazuhiro, Yagi, Takahito, Yamamoto, Kazuhide

“…Runt-related transcription factor 3 (RUNX3) is known as a tumor suppressor gene for gastric cancer and other cancers, this gene may be involved in the…”
Get full text

Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma by Miyatake, Hirokazu, Kobayashi, Yoshiyuki, Iwasaki, Yoshiaki, Nakamura, Shin-ichiro, Ohnishi, Hideki, Kuwaki, Kenji, Toshimori, Junichi, Hagihara, Hiroaki, Nouso, Kazuhiro, Yamamoto, Kazuhide

“…Background and Aims Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC)…”
Get full text

Prevention of vagotonia and pain during radiofrequency ablation of liver tumors by Nakamura, Shinichiro, Nouso, Kazuhiro, Onishi, Hideki, Kuwaki, Kenji, Hagihara, Hiroaki, Takeuchi, Yasuto, Wada, Nozomu, Morimoto, Yuki, Miyahara, Koji, Yasunaka, Tetsuya, Ikeda, Fusao, Miyake, Yasuhiro, Kobayashi, Yoshiyuki, Shiraha, Hidenori, Ishikawa, Shinichi, Takaki, Akinobu, Yamamoto, Kazuhide

“…Radiofrequency ablation (RFA) is frequently used to treat early stage hepatocellular carcinoma. Two of the most cumbersome side‐effects of the ablation…”
Get full text

Serum oxidative-anti-oxidative stress balance is dysregulated in patients with hepatitis C virus-related hepatocellular carcinoma by Nishimura, Mamoru, Takaki, Akinobu, Tamaki, Naofumi, Maruyama, Takayuki, Onishi, Hideki, Kobayashi, Sayo, Nouso, Kazuhiro, Yasunaka, Tetsuya, Koike, Kazuko, Hagihara, Hiroaki, Kuwaki, Kenji, Nakamura, Shinichiro, Ikeda, Fusao, Iwasaki, Yoshiaki, Tomofuji, Takaaki, Morita, Manabu, Yamamoto, Kazuhide

“…Aim Oxidative stress is associated with progression of chronic liver disease (CLD). This association is best established in chronic hepatitis C. However, the…”
Get full text

Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma by Miyahara, Koji, Nouso, Kazuhiro, Morimoto, Yuki, Takeuchi, Yasuto, Hagihara, Hiroaki, Kuwaki, Kenji, Onishi, Hideki, Ikeda, Fusao, Miyake, Yasuhiro, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Iwadou, Shouta, Kobayashi, Yoshiyuki, Takaguchi, Koichi, Takuma, Yoshitaka, Takabatake, Hiroyuki, Sakaguchi, Kohsaku, Yamamoto, Kazuhide

“…Aim We investigated whether continuous sorafenib administration keeps suppressing the growth of hepatocellular carcinoma (HCC) after first progressive disease…”
Get full text

Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma by Kobayashi, Sayo, Nouso, Kazuhiro, Kinugasa, Hideaki, Takeuchi, Yasuto, Tomoda, Takeshi, Miyahara, Koji, Hagihara, Hiroaki, Kuwaki, Kenji, Onishi, Hideki, Nakamura, Shinichiro, Ikeda, Fusao, Miyake, Yasuhiro, Shiraha, Hidenori, Takaki, Akinobu, Yamamoto, Kazuhide

“…Aim:  Hepatocellular carcinoma (HCC) is a common clinical problem all over the world. Fucosylated hemopexin (Fuc‐Hpx) is a newly reported glycoprotein for the…”
Get full text

The diagnosis of hypovascular hepatic lesions showing hypo-intensity in the hepatobiliary phase of Gd-EOB- DTPA-enhanced MR imaging in high-risk patients for hepatocellular carcinoma by Nakamura, Shinichiro, Nouso, Kazuhiro, Kobayashi, Yoshiyuki, Shiraha, Hidenori, Ohnishi, Hideki, Toshimori, Junichi, Kuwaki, Kenji, Hagihara, Hiroaki, Takayama, Hiroki, Yamamoto, Kazuhide

“…The aim of this study was to evaluate the histologic diagnosis of hypovascular hepatic lesions showing hypointensity on hepatobiliary phase images of…”
Get full text

Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma by Miyahara, Koji, Nouso, Kazuhiro, Morimoto, Yuki, Tomoda, Takeshi, Kobayashi, Sayo, Takeuchi, Yasuto, Hagihara, Hiroaki, Kuwaki, Kenji, Ohnishi, Hideki, Ikeda, Fusao, Miyake, Yasuhiro, Nakamura, Shinichiro, Shiraha, Hidenori, Takaki, Akinobu, Yamamoto, Kazuhide

“…Aim Des‐γ‐carboxyprothrombin (DCP) is known to be increased by the use of sorafenib for the treatment of hepatocellular carcinoma (HCC), despite its…”
Get full text

Diagnostic usefulness of precise examinations with intraductal ultrasonography, peroral cholangioscopy and laparoscopy of immunoglobulin G4‐related sclerosing cholangitis by Horiguchi, Shigeru, Ikeda, Fusao, Shiraha, Hidenori, Yamamoto, Naoki, Sakakihara, Ichiro, Noma, Yasuhiro, Tsutsumi, Koichiro, Kato, Hironari, Hagihara, Hiroaki, Yasunaka, Tetsuya, Nakamura, Shinichiro, Kobashi, Haruhiko, Kawamoto, Hirofumi, Yamamoto, Kazuhide

“…Herein, a case of immunoglobulin G4 (IgG4)‐related sclerosing cholangitis is reported. IgG4 was diagnosed based on observations from peroral cholangioscopy and…”
Get full text

Hepatocellular carcinoma occurring in hepatobiliary fibropolycystic disease by Kinugasa, Hideaki, Nouso, Kazuhiro, Kobayashi, Yoshiyuki, Yasunaka, Tetuya, Onishi, Hideki, Nakamura, Shin‐ichiro, Shiraha, Hidenori, Takayama, Hiroki, Toshimori, Junichi, Kuwaki, Kenji, Hagihara, Hiroaki, Miyake, Yasuhiro, Ikeda, Fusao, Takaki, Akinobu, Kobashi, Haruhiko, Yamamoto, Kazuhide

“…Congenital hepatic fibrosis (CHF) and bile duct hamartomas (von Meyenburg complexes) are hepatobiliary fibropolycystic diseases. There have been several…”
Get full text

Prognostic model for hepatocellular carcinoma with time-dependent factors by Kuwaki, Kenji, Nouso, Kazuhiro, Kobayashi, Yoshiyuki, Nakamura, Shinichiro, Ito, Yoichi M, Iwadou, Shouta, Hagihara, Hiroaki, Yasunaka, Tetsuya, Toshimori, Junichi, Miyatake, Hirokazu, Miyoshi, Kenji, Onishi, Hideki, Miyake, Yasuhiro, Shoji, Bon, Takaki, Akinobu, Shiraha, Hidenori, Iwasaki, Yoshiaki, Kobashi, Haruhiko, Yamamoto, Kazuhide

“…The purpose of this study was to build a prognostic model of hepatocellular carcinoma (HCC) using time-dependent covariates to re-evaluate the prognosis at any…”
Get full text

Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab by Kikuchi, Tatsuya, Takeuchi, Yasuto, Nouso, Kazuhiro, Kariyama, Kazuya, Kuwaki, Kenji, Toshimori, Junichi, Iwado, Shota, Moriya, Akio, Hagihara, Hiroaki, Takabatake, Hiroyuki, Tada, Toshifumi, Yasunaka, Tetsuya, Sakata, Masahiro, Sue, Masahiko, Miyake, Nozomi, Adachi, Takuya, Wada, Nozomu, Onishi, Hideki, Shiraha, Hidenori, Takaki, Akinobu, Otsuka, Motoyuki

“…Background To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and…”
Get full text